Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. May 28, 2014; 20(20): 6006-6012
Published online May 28, 2014. doi: 10.3748/wjg.v20.i20.6006
Table 1 Summary of studies comparing the impact of anti-viral treatment vs no treatment in hepatocellular carcinoma recurrence
Ref.AntiviralTreated with antiviral
OR (95%CI)
Wu et al[41]Nucleoside analogue518106405117650.67 (0.55-0.81)
Li et al[33]Lamivudine433336330.30 (0.08-1.19)
Koda et al[30]Nucleoside analogue221714120.57 (0.09-3.42)
Chuma et al[34]Lamivudine, adefovir dipivoxil or entecavir20864222.57 (1.34-4.94)
Hung et al[31]Lamivudine10062300.05 (0.00-0.90)
Kuzuya et al[35]Lamivudine16733150.93 (0.28-3.11)
Kubo et al[36]Lamivudine1421050.17 (0.02-1.16)
Shuqun et al[38]Lamivudine and thymosin alpha1161417170.17 (0.01-3.73)
Piao et al[37]Lamivudine301440260.47 (0.18-1.19)